全文获取类型
收费全文 | 58586篇 |
免费 | 4216篇 |
国内免费 | 117篇 |
专业分类
耳鼻咽喉 | 509篇 |
儿科学 | 2134篇 |
妇产科学 | 1923篇 |
基础医学 | 7120篇 |
口腔科学 | 729篇 |
临床医学 | 9782篇 |
内科学 | 10466篇 |
皮肤病学 | 840篇 |
神经病学 | 5353篇 |
特种医学 | 1063篇 |
外国民族医学 | 33篇 |
外科学 | 5501篇 |
综合类 | 876篇 |
一般理论 | 87篇 |
预防医学 | 8081篇 |
眼科学 | 704篇 |
药学 | 3494篇 |
1篇 | |
中国医学 | 90篇 |
肿瘤学 | 4133篇 |
出版年
2023年 | 322篇 |
2022年 | 488篇 |
2021年 | 1079篇 |
2020年 | 726篇 |
2019年 | 1170篇 |
2018年 | 1331篇 |
2017年 | 938篇 |
2016年 | 1049篇 |
2015年 | 1151篇 |
2014年 | 1572篇 |
2013年 | 2636篇 |
2012年 | 3766篇 |
2011年 | 4023篇 |
2010年 | 2168篇 |
2009年 | 2017篇 |
2008年 | 3529篇 |
2007年 | 4054篇 |
2006年 | 3890篇 |
2005年 | 3785篇 |
2004年 | 3650篇 |
2003年 | 3450篇 |
2002年 | 3283篇 |
2001年 | 630篇 |
2000年 | 556篇 |
1999年 | 606篇 |
1998年 | 744篇 |
1997年 | 583篇 |
1996年 | 525篇 |
1995年 | 435篇 |
1994年 | 433篇 |
1993年 | 422篇 |
1992年 | 473篇 |
1991年 | 452篇 |
1990年 | 448篇 |
1989年 | 394篇 |
1988年 | 401篇 |
1987年 | 394篇 |
1986年 | 345篇 |
1985年 | 329篇 |
1984年 | 344篇 |
1983年 | 322篇 |
1982年 | 349篇 |
1981年 | 336篇 |
1980年 | 270篇 |
1979年 | 253篇 |
1978年 | 214篇 |
1977年 | 219篇 |
1976年 | 194篇 |
1974年 | 203篇 |
1973年 | 193篇 |
排序方式: 共有10000条查询结果,搜索用时 8 毫秒
21.
Sally Urang Lorna Davis Charlotte Cram Elsberry Mary Kay Kozlowski 《Journal of Midwifery & Women's Health》1993,38(Z1):95s-99s
Fetal scalp blood sampling (FSBS), in conjunction with fetal heart rate monitoring, is a method of fetal surveillance that may avoid cesarean delivery of the healthy fetus or indicate the need for immediate delivery of a compromised fetus. Some researchers have recently begun to question the efficacy of FSBS. In this article, three nurse-midwives discuss FSBS as a tool in assessing fetal well-being during labor and consider whether FSBS is a nurse-midwifery procedure. 相似文献
22.
23.
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies
Bayard L. Powell Hyman B. Muss Robert L. Capizzi Mary E. Caponera Douglas R. White Patricia J. Zekan James N. Atkins Don V. Jackson Jr. Frederick Richards II John B. Craig Julia M. Cruz Charles L. Spurr 《Cancer chemotherapy and pharmacology》1987,19(3):250-252
Summary Cytosine arabinsodie (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9–12 and 21–24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2×2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.Supported in part by grants from the National Cancer Institute (CA-12197 and CA-09422) and the American Cancer Society CF-85-182 相似文献
24.
25.
26.
The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy 总被引:4,自引:0,他引:4
K L Griem I C Henderson R Gelman D Ascoli B Silver A Recht R L Goodman S Hellman J R Harris 《Journal of clinical oncology》1987,5(10):1546-1555
The use of adjuvant radiation therapy in breast cancer patients treated with mastectomy and adjuvant chemotherapy has been controversial. In order to assess the necessity and effectiveness of adjuvant radiation therapy in this setting, we reviewed the results in 510 patients with T1-T3 tumors and pathologically positive nodes or tumors larger than 5 cm and negative nodes who were treated with adjuvant chemotherapy. Patients with four or more positive nodes or at least one positive apical node were randomized to receive either five or ten cycles of cyclophosphamide/Adriamycin (Adria Laboratories, Columbus, OH) (CA) and patients with one to three positive nodes or operable tumors larger than 5 cm and pathologically negative nodes were randomized to receive eight cycles of either cyclophosphamide, methotrexate, and 5-fluorouracil (5-FU) (CMF) or methotrexate and 5-FU (MF) chemotherapy. Two hundred six of these patients were subsequently rerandomized to receive either no further treatment or adjuvant radiotherapy. Thirty-five patients withdrew after randomization, including 34 who declined to receive radiotherapy. Radiation therapy consisted of 4,500 cGy in 5 weeks to the chest wall and appropriate draining lymph nodes. Median follow-up from chemotherapy randomization is 45 months for patients in the CA arm and 53 months for those in the CMF/MF arm. The crude rate of local failure (chest wall or draining lymph node areas) as first site of failure for patients randomized to receive chemotherapy only was 14%; for those randomized to receive both chemotherapy and radiotherapy it was 5% (P = .03). For patients in the CMF/MF arm, the rate of local failure as the first site of failure was nearly the same for patients randomized to chemotherapy only as for those randomized to adjuvant radiotherapy as well (5% v 2%). For patients in the CA arm, the crude rate of local failure was 20% for patients randomized to receive chemotherapy only, and 6% for those randomized to both types of adjuvant treatment (P = .03). Among the 43 patients treated with CA who actually received radiotherapy, there was only one local failure, compared with 12 local failures among the 59 patients (20%) who actually did not receive radiotherapy (P = .007). No significant difference was seen in disease-free survival or overall survival in either the CA or the CMF/MF arm between patients randomized to receive radiation therapy and those randomized to no further treatment.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献
27.
28.
29.
30.